Posted by Michael Wonder on 05 May 2022
Novavax requests expanded authorisation of Nuvaxovid COVID-19 vaccine to adolescents aged 12 through 17 years in Great Britain
4 May 2022 - If granted, Nuvaxovid would be the first protein based COVID-19 vaccine option authorised for adolescents in Great Britain
Novavax today announced the submission of a request to the MHRA in Great Britain to expand the authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine (recombinant, adjuvanted), for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in adolescents aged 12 through 17 years.
